"HLA-A2 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
| Descriptor ID |
D015789
|
| MeSH Number(s) |
D12.776.395.550.489.400.020 D12.776.543.550.439.400.020 D23.050.301.500.100.400.020 D23.050.301.500.450.370.020 D23.050.705.552.100.400.020 D23.050.705.552.450.370.374
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-A2 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A2 Antigen".
This graph shows the total number of publications written about "HLA-A2 Antigen" by people in this website by year, and whether "HLA-A2 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A2 Antigen" by people in Profiles.
-
Gene editing of CD3 epsilon to redirect regulatory T?cells for adoptive T?cell transfer. Mol Ther. 2025 Mar 05; 33(3):997-1013.
-
Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. Cell Rep Methods. 2024 Nov 18; 4(11):100906.
-
Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells. Front Immunol. 2020; 11:607.
-
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
-
Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
-
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84.
-
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother. 2012 Jul; 61(7):1125-36.
-
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75.
-
Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays. J Immunol Methods. 2011 Nov 30; 374(1-2):13-7.